| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA919: Rimegepant for treating migraine |
|
Medicine details |
|
| Medicine name | rimegepant (Vydura®) |
| Formulation | 75 mg oral tablet |
| Reference number | 3695 |
| Indication | Acute treatment of migraine with or without aura in adults and preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month |
| Company | Biohaven Pharmaceuticals Inc |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/06/2022 |
| NICE guidance | |